Skip to main content

Advertisement

SpringerLink
Log in

Heterogeneous lymphokine-activated killer cell precursor populations

Development of a monoclonal antibody that separates two populations of precursors with distinct culture requirements and separate target-recognition repertoires

  • Original Articles
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Summary

We developed a monoclonal antibody (mAb) 211, which recognizes the precursors in peripheral blood of lymphokine-activated killer cells (LAK) induced by recombinant interleukin-2 (rIL-2). In conjunction with complement mAb 211 also eliminates natural killer cells (NK) and a majority of the cytotoxic T lymphocytes. B cells and monocytes do not express the 211 antigen. Since mAb 211 recognized such a large percentage of peripheral blood lymphocytes we examined which 211+ subpopulation was the predominant precursor of rIL-2-induced LAK cells using two-color fluoresence-activated cell sorting (fluorescein-conjugated 211 mAb plus phycoerythrin-CD11b). This method identified the 211+/ CD11b+ population as the predominant phenotype of the rIL-2-induced LAK precursor. In addition, we directly compared the phenotype of the LAK precursor induced by delectinated T-cell growth factor (TCGF) to that induced by rIL-2. The 211-depleted population, which was devoid of NK cells and LAK precursors (inducible by rIL-2), was capable of generating LAK activity when TCGF was used as the source of lymphokine. LAK cells induced by TCGF from the 211-depleted population lysed a fresh sarcoma and an NK-resistant cultured melanoma tumor target but not the Daudi cell line, which was lysed by rIL-2-induced LAK cells. Lymphoid subpopulations, depleted using NKH1a mAb, behaved similarly, generating high levels of lysis against the two solid tumor targets when cultured with TCGF but not with rIL-2. CD 3-depleted populations showed enrichment for LAK precursors using either rIL-2 or TCGF. These results indicate that while rIL-2-induced LAK precursors cannot be separated from cells with NK activity, TCGF-induced LAK cells can be generated from populations of peripheral blood mononuclear cells without NK activity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bevan MJ, Cohen M (1975) Cytotoxic effects of antigen- and mitogen-induced T cells on various targets. J Immunol 114:559

    Google Scholar 

  2. Ferrini S, Miescher S, Zocchi MR, Fliedner VV, Moretta A (1987) Phenotypic and functional characterization of recombinant interleukin 2 induced activated killer cells: analysis at the population and clonal levels. J Immunol 138:1297

    Google Scholar 

  3. Golub SH, Golightly MG, Zielske JV (1979) “NK-like” cytotoxicity of human lymphocytes cultured in media containing fetal bovine serum. Int J Cancer 24:273

    Google Scholar 

  4. Grimm EA, Rosenberg SA (1984) The human lymphokine-activated killer cell phenomenon. In: Lymphokines, vol 9. Academic Press, Orlando, Fla, p 279

    Google Scholar 

  5. Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA (1982) Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin-2-activated autologous human peripheral blood lymphocytes. J Exp Med 155:1823

    Article  CAS  PubMed  Google Scholar 

  6. Grimm EA, Ramsey KM, Mazumder A, Wilson DJ, Djeu JY, Rosenberg SA (1983) Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymusderived lymphocytes, and natural killer cells. J Exp Med 157:884

    Google Scholar 

  7. Itoh K, Tilden AB, Kumagai K, Balch CM (1985) Leu 11 positive lymphocytes with natural killer activity are precursors of recombinant interleukin 2-induced activated killer cells. J Immunol 134:802

    Google Scholar 

  8. Itoh K, Tilden AB, Balch CM (1986) Lysis of human solid tumor cells by lymphokine-activated natural killer cells. J Immunol 136:3910

    Google Scholar 

  9. Lanier LL, Benike CJ, Phillips JH, Engleman EG (1985) Recombinant interleukin 2 enhanced natural killer cell-mediated cytotoxicity in human lymphocyte subpopulations expressing the Leu 7 and Leu 11 antigens. J Immunol 134:794

    Google Scholar 

  10. Reference deleted

  11. Lotze MT, Grimm EA, Mazumder A, Strausser JL, Rosenberg SA (1981) Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor. Cancer Res 41:4420

    Google Scholar 

  12. Mule JJ, Smith CA, Rosenberg SA (1987) Interleukin 4 (B cell stimulatory factor 1) can mediate the induction of lymphokine-activated killer cell activity directed against fresh tumor cells. J Exp Med 166:792

    Google Scholar 

  13. Mule JJ, Krosnick JA, Rosenberg SA (1989) IL-4 regulation of murine lymphokine activated killer activity in vitro: effects on the IL-2-induced expansion, cytotoxicity, and phenotype of lymphokine-activated killer effectors. J Immunol 142:726

    Google Scholar 

  14. Muul LM, Rosenberg SA (1987) New approaches to the immunotherapy of cancer based on the systemic administration of lymphokine-activated killer cells and recombinant interleukin 2. In: Cinader B, Miller RG (eds) Progress in immunology VI. Academic Press, Orlando, Fla, p 714

    Google Scholar 

  15. Ortaldo JR, Mason A, Overton R (1986) Lymphokine-activated killer cells. Analysis of progenitors and effectors. J Exp Med 164:1193

    Google Scholar 

  16. Owen-Schaub LB, Gutterman JU, Grimm EA (1988) Synergy of tumor necrosis factor and interleukin 2 in the activation of human cytotoxic lymphocytes: Effect of tumor necrosis factor and interleukin 2 in the generation of human lymphokine-activated killer cell cytotoxicity. Cancer Res 48:788

    Google Scholar 

  17. Phillips JH, Lanier LL (1986) Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis. J Exp Med 164:814

    Google Scholar 

  18. Roberts K, Lotze MT, Rosenberg SA (1987) The lymphokine activated killer cell. I. Separation and functional studies of the human precursor and effector cell. Cancer Res 47:4366

    Google Scholar 

  19. Rosenberg SA, Grimm EA, McGrogan M, Doyle M, Kawasaki E, Koths K, Mark DF (1984) Biological activity of recombinant human interleukin-2 produced in Escherichia coli. Science 223:1412

    CAS  PubMed  Google Scholar 

  20. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson CG, White DE (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high dose interleukin-2 alone. N Engl J Med 316:889

    CAS  PubMed  Google Scholar 

  21. Rosenstein M, Yron I, Kaufman Y, Rosenberg SA (1984) Lymphokine-activated killer cells: lysis of fresh syngeneic natural killer-resistant murine tumor cells by lymphocytes cultured in interleukin 2. Cancer Res 44:1946

    Google Scholar 

  22. Sharp TA, Gress RE, Sachs DH, Rosenberg SA (1985) Assessment of mixed lymphocyte reactivity in human bone marrow cell cultures. Transplant 40:551

    Google Scholar 

  23. Skibber J, Lotze MT, Uppenkamp I, Ross W, Rosenberg SA (1987) Identification and expansion of human lymphokine-activated killer cells: implications for the immunotherapy of cancer. J Surg Res 42:613

    Google Scholar 

  24. Springer TA (1981) Monoclonal antibody analysis of complex biological systems. Combination of cell hybridization and immunoadsorbents in a novel cascade procedure and its application to the macrophage cells surface. J Biol Chem 256:3833

    Google Scholar 

  25. Tilden AB, Itoh K, Balch CM (1987) Human lymphokine-activated killer (LAK) cells: identification of two types of effector cells. J Immunol 138:1068

    Google Scholar 

  26. Trinchieri G, Matsumoto-Kobayashi M, Clark SC, Seehra J, London L, Perussia B (1984) Response of resting human peripheral blood natural killer cells to interleukin 2. J Exp Med 160:1147

    Google Scholar 

  27. Widmer MB, Acres RB, Sassenfeld HM, Grabstein KM (1987) Regulation of cytolytic cell populations from human peripheral blood by B cell stimulatory factor 1 (interleukin 4). J Exp Med 166:1447

    Google Scholar 

  28. Yang JC, Mule JJ, Rosenberg SA (1986) Murine lymphokine-activated killer (LAK) cells; phenotypic characterization of the precursor and effector cells. J Immunol 137:715

    Google Scholar 

  29. Yron I, Wood TA Jr, Spiess PJ, Rosenberg SA (1980) In vitro growth of murine T cells V. The isolation and growth of lymphoid cells infiltrating syngeneic solid tumors. J Immunol 125:238

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA

    Bernard A. Fox & Steven A. Rosenberg

Authors
  1. Bernard A. Fox
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Steven A. Rosenberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fox, B.A., Rosenberg, S.A. Heterogeneous lymphokine-activated killer cell precursor populations. Cancer Immunol Immunother 29, 155–166 (1989). https://doi.org/10.1007/BF00199990

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00199990

Keywords

Search

Navigation